Ann: Appendix 4C - Quarterly, page-14

@Mangoman605 YOu've bagged me plenty before MM. You don't get free rib punches.

At the hope of keeping this adult like and useful to others, I expect further good % revenue increases in the Appendix 4C this Friday from Striate and SAS use of CelGro/ATI treatments domestically. Unfortunately, still a good way from making OCC cash flow positive, such are the low absolute values at this early stage and lethargic KOL route. Hence as said, hoping for some more information on Remplir/FDA as that (or obviously a partnership) promises a quicker route to becoming free cash flow positive.

Little stem cell news out of the US lately, focus having been mainly in CAR-T cell developments. Last one two weeks ago, FDA granting an IND, for an MSc stem cells stock I am on small in the US (and losing money):

https://www.clinicaltrialsarena.com/news/biocardia-covid-stem-cell-therapy/